US Market Report for Motion Preservation Devices 2017 - MedCore

US Market Report for Motion Preservation Devices 2017 - MedCore

  • April 2017 •
  • 471 pages •
  • Report ID: 4821697
Description
General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions

This increase in the market has primarily been maintained by ongoing growth in the two artificial disc markets, although dynamic stabilization makes up a consistent proportion. The U.S. motion preservation device market emerged in 2004 when DePuy’s Charité® LAD was first sold. Synthes’ ProDisc®-L LAD and Medtronic’s X-STOP® IPD devices were both released in 2006.

CAD and AR devices subsequently entered the market in 2007. As the spinal implant market grows in size, more competitors are entering the markets and broadening their portfolios with new products including motion preservation implants. The nucleus replacement device (NRD) market and facet arthroplasty (FA) market were both expected to emerge around 2013 and 2014; but, as neither product has received FDA approval, it is unknown when these products will enter the market and if they will even have a significant impact on the markets for currently existing products. Procedure number growth, as well as favorable reimbursement policies, will drive the motion preservation device market. Strong growth rates will be maintained going forward due to the release of multiple products in established segments such as artificial discs.

Abstract
Motion preservation devices are an exciting and often controversial segment of the spinal implant market. These devices are used for treating pathologies similar to those that spinal fusion procedures address. However, unlike spinal fusion, motion preservation devices act to preserve the natural motion of the spine. Some motion preservation devices are used for treating pathologies that were previously untreatable with traditional fusion procedures, thus creating new markets for spinal implants.

Scope:
2013-2023